Apretude (cabotegravir) for the Treatment of HIV-1 Pre-Exposure Prevention (PrEP), US
Apretude (cabotegravir) is the first and only injectable long-acting pre-exposure prevention (PrEP) treatment to minimise the risk of sexually acquired HIV-1. The drug was developed by ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK), Pfizer …